"I want to emphasize that, because the FDA has not approved pediatric labeling for our products, Forest has always been scrupulous about not promoting the pediatric use of our antidepressant drugs, ...

The Supreme Court meant what it said in China Agritech, Inc. v. Resh – that is the primary lesson from the First Circuit’s January 30 th decision in In re Celexa and Lexapro Marketing and Sales ...

The Department of Justice (DOJ) is suing Forest Laboratories over the alleged promotion of Celexa and Lexapro off-label, for pediatric use. Forest also paid kickbacks to physicians in return for ...

Employees of Forest Labs and that company's rivals should read the U.S. government's complaint against the company, which alleges off-label promotion of Lexapro and Celexa for use in children. The ...

ST. LOUIS (CN) - Forest Pharmaceuticals and Forest Laboratories illegally marketed two antidepressant drugs, Celexa and Lexapro, a class action claims in Federal Court. Named plaintiffs Universal Care ...

NEW YORK, March 20 (Reuters) - Just weeks after prosecutors accused Forest Laboratories Inc of illegally marketing its anti-depressants Celexa and Lexapro to children and paying pediatricians ...

Fifty-four lawsuits, mostly involving suicides and attempted suicides by teenagers in various parts of the country, accuse the New York-based pharmaceutical company of concealing a negative pediatric ...

The U.S. Department of Justice has filed a complaint against Forest Laboratories, the maker of antidepressants Celexa and Lexapro, accusing it of being underhanded in how it disclosed its research.

WASHINGTONWASHINGTON — Forest Pharmaceuticals Inc. has agreed to pay more than $313 million and plead guilty to obstruction of justice, distribution of the then-unapproved drug Levothroid and illegal ...

On April 20, the FDA approved a revision to the safety labeling for citalopram hydrobromide and escitalopram oxalate (Celexa and Lexapro, respectively, made by Forest Laboratories) in tablet and oral ...